VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE

May 12, 2000

Slides

Introduction and Interim Policy, Dr. Andrew Lewis, FDA .pdf

CBER Research Related to Neoplastic Cell Lines, Dr. Philip krause, FDA .pdf